Updated Jul 16, 2026
Neervannan Seshadri is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $1.61M.
Neervannan Seshadri is the Chief Operating Officer at Tarsus Pharmaceuticals, Inc., a biotechnology company focused on developing innovative therapies for eye diseases. His role involves overseeing the company's operations and strategic initiatives.
| Role | Chief Operating Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-24 | TARS | Tarsus Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 3.0K | $66.75 | $200K |
| 2026-03-19 | TARS | Tarsus Pharmaceuticals, Inc. | S — Open-market sale | 4.6K | $67.00 | $307K |
| 2026-03-19 | TARS | Tarsus Pharmaceuticals, Inc. | S — Open-market sale | 3.6K | $68.71 | $248K |
| 2026-03-19 | TARS | Tarsus Pharmaceuticals, Inc. | S — Open-market sale | 3.1K | $69.42 | $217K |
| 2026-03-17 | TARS | Tarsus Pharmaceuticals, Inc. | M — Option exercise | 26.3K | — | |
| 2026-03-05 | TARS | Tarsus Pharmaceuticals, Inc. | S — Open-market sale [10b5-1] | 8.4K | $76.67 | $641K |
Neervannan Seshadri is the Chief Operating Officer at Tarsus Pharmaceuticals, Inc., a biotechnology company focused on developing innovative therapies for eye diseases. His role involves overseeing the company's operations and strategic initiatives.…
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($1.61M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Neervannan Seshadri profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.